QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vivian, E. M Search for Related Content PubMed PubMed Citation Articles by Vivian, E. M

Should Drug Therapy Be Personalized Based on Race?

Associate Professor of Clinical Pharmacy, College of Pharmacy, Western University of Health Sciences, 309 E. Second St., Pomona, CA 91766-1854, fax 909/469-5539, evivian{at}westernu.edu

Reprints: Dr. Vivian.

The A-HeFT (African American Heart Failure Trial) showed that isosorbide/hydralazine was associated with significant reductions in mortality in African Americans with heart failure compared with placebo. The results of a recently published genetic substudy identified a gene variant related to nitric oxide synthase production that attributed to the treatment response observed in patients enrolled in the A-HeFT. This finding suggests that isosorbide/hydralazine's ability to improve heart failure outcomes is tied to a genetic trait that may be more prevalent in African Americans than whites, but is not necessarily related to perceived race.

Key Words: A-HeFT, African American, prescribing

Published Online, February 28, 2006. www.theannals.com, DOI 10.1345/aph.1G533